Focus

Genetics Investors: Angels and VC Firms

The RaiseHunt database lists 1,411 Genetics investors: 28 angel investors and 1,383 people at 227 firms. Most list Series A and Seed among their stages; the largest hubs are San Francisco, Boston and New York.

Strongest in San Francisco, Boston and New York

Common stages: Series A and Seed

1,411
Genetics investors
28
Angel investors
1,383
People at VC/PE firms
227
Firms tagged

Skip the browsing. Let AI find your ideal investors in one minute.

Paste your startup website and AI picks your best-fit investors out of 135,000+ profiles.

1,411 Genetics investors

Showing 1-20

Filters
Axel Nitsch
Axel Nitsch

angel investor

Bonn, Germany
Angel
ConsumerHealthcare
View profile
Mark Stoner
Mark Stoner

angel investor and operator angel

San Francisco, United States
AngelOperator angel
AIFinTech
View profile
Michael Bauer
Michael Bauer

Managing Director

New York, United States
Private equityVenture debt
ConsumerFinTech
View profile
Joerg Feldmann
Joerg Feldmann

Genesys Solution Partner

Cologne, Germany
Corporate VCVenture capital
AIHealthcare
View profile
William Tan
William Tan

Investment Professional

San Francisco, United States
Private equity
ClimateCommerce
View profile
Alain Huriez
Alain Huriez

Chairman & Managing Partner

Paris, France
Venture capital
Healthcare
View profile
Boston, United States
Private equityVenture capital
FinTechHealthcare
View profile
Sausalito, United States
Venture capital
Healthcare
View profile
Bharat Srinivasa
Bharat Srinivasa

Founder. Investor. Partner

Toronto, Canada
Venture capital
AIHealthcare
View profile
Aaron Mankovski
Aaron Mankovski

Managing Partner

Tel Aviv, Israel
Venture capital
AICommerce
View profile
John Glasspool
John Glasspool

Venture Partner

Boston, United States
Venture capital
AIHealthcare
View profile
Washington, United States
Private equityVenture debt
ClimateConsumer
View profile
Berkeley, United States
AcceleratorVenture capital
AIFinTech
View profile
Kelly Holman
Kelly Holman

Managing Director

Toronto, Canada
Corporate VCVenture capital
AIHealthcare
View profile
Jenna Hebert
Jenna Hebert

Investment Director

Boston, United States
Private equityVenture capital
FinTechHealthcare
View profile
Boston, United States
Private equityVenture capital
FinTechHealthcare
View profile
New York, United States
Private equityVenture capital
FinTechHealthcare
View profile
San Francisco, United States
Fund of fundsPrivate equity
HardwareHealthcare
View profile
Montreal, Canada
Venture capital
AIHealthcare
View profile
Cambridge, United States
Private equityVenture capital
FinTechHealthcare
View profile

900 of 1,411 Genetics investors, A to Z

Grouped by first letter. Name and profile link only, the detailed rows are in the table above.
Show

A92

B37

C54

D64

E34

F14

G34

H29

I5

J107

K43

L30

M84

N33

O9

P38

Q1

R54

S60

T33

U1

V16

W11

Y9

Z8

Frequently asked questions

How many Genetics investors are on RaiseHunt?

RaiseHunt currently lists 1,411 Genetics investors.

Are Genetics investors angels or funds?

Both. 28 are angel investors putting in their own money, and 1,383 are people making investment decisions at 227 firms.

Where are most Genetics investors based?

The largest concentrations are in San Francisco, Boston and New York.

What stage do Genetics investors invest at?

Most list Series A and Seed among the rounds they take part in.

How do I contact Genetics investors?

Every profile shows whether an email address is on file. The addresses themselves, along with AI matching and outreach, are in the RaiseHunt app.

Is the list of Genetics investors free to browse?

Yes. The directory and every profile page are free to read. Matching your own startup against them requires an account.

Do Genetics investors only back Genetics companies?

No. A focus area is a signal of interest, not a restriction. Investors usually list several, and the useful question is whether their existing portfolio looks like the kind of company you are building.

Should I raise from one investor or several?

Several, in almost every case. A single backer concentrates the risk of the round collapsing if that one conversation goes cold, and a group brings more introductions later. Rounds are usually assembled from a lead plus others who follow.

How do I follow up without being annoying?

Follow up with new information rather than a reminder. A short note saying what changed since you last wrote gives the reader a reason to reply, where "just checking in" gives them none. Two or three of those, spaced out, is normal and expected.

What if no Genetics investor replies?

Usually the list was too short or too loosely matched, not that the company is unfundable. Widen it, tighten who you are writing to, and rewrite the first two lines of the message. Those lines decide whether anything below them gets read.

What is the difference between an angel investor and a VC fund?

An angel invests their own money and can decide alone, which usually makes the process shorter. A fund invests money it raised from other people, so it answers to those backers and normally runs a longer diligence process before it commits. Founders often raise from angels first and bring in a fund once there is more to show.

How many Genetics investors should I contact?

Far more than feels comfortable. Response rates on cold outreach are low even when the fit is good, so a list of a handful of perfect names tends to stall. Build a long list, sort it by how well each one matches what you are building, and work down it in batches rather than sending everything at once.

Data: RaiseHunt investor dataset · Snapshot 26 September 2026 · How this data is built · Report a correction or request removal